TrialBritish journal of haematology2025

Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm.

Stéphane De Botton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.